Interest in Use of Fewer Radiation Treatments Across Cancer Types is Accelerating, Says Expert

Video

Data presented at a recent medical conference shows that there is continued interest in observing the effects of fewer radiation treatments across several cancer types, according to an expert.

The use of hypofractionated radiation—fewer radiation treatments at larger doses—in several cancer types is accelerating, according to an expert.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, CancerNetwork® spoke with Louis Potters, MD, FACR, FABS, FASTRO, about some of the potentially practice-changing results in the radiation oncology space that were presented at the conference.

Potters, who is the chair of the Department of Radiation Medicine and deputy physician-in-chief of Northwell Health Cancer Institute in New Hyde Park, New York, said that the accelerated use of hypofractionated radiation, especially in the prostate and breast cancer settings, as well as using radiation to manage oligometastatic disease were some key overarching themes of the data seen at ASTRO.

Transcript:

I really did enjoy the meeting a lot this year; there was a lot of really good science. Not only that, it was really nice seeing colleagues and friends after not having seen them for the last number of years. If one was to take away an overall theme from the meeting, it was the continued acceleration of hypofractionation: the idea of using fewer treatments for any disease in particular. There was a lot of data on breast and prostate [cancer]. Secondly, an overarching macro-theme was the opportunity to use radiation for oligometastatic disease. There was discussion about prostate cancer in particular [and] other diseases as well in either a curative approach or in a palliative type of setting.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
Related Content
Vikek S. Kavadi, MD, MBA, FASTRO, succeeds Laura Thevenot, who plans to retire at the end of 2024 after leading the organization since 2002.

American Society for Radiation Oncology Names Vivek S. Kavadi as CEO

Roman Fabbricatore
June 25th 2024
Article

Vikek S. Kavadi, MD, MBA, FASTRO, succeeds Laura Thevenot, who plans to retire at the end of 2024 after leading the organization since 2002.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

Russ Conroy
April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Stereotactic Radiation Appears Effective in Primary Renal Cell Cancer

Russ Conroy
March 20th 2024
Article

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

Evidence Shows Racial Disparities in Radiation Oncology for Breast Cancer

Russ Conroy
March 8th 2024
Article

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.